The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

But it remains costly — and controversial Health Canada approved a prescription esketamine nasal spray called Spravato in ...

( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Legal Disclaimer: ...

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side effects.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

Spravato has been the subject of much hyperbole since its registration trials first showed that the drug seems to work much more quickly than current antidepressants, with its effects kicking in ...